68
Participants
Start Date
August 5, 2020
Primary Completion Date
January 6, 2025
Study Completion Date
November 5, 2027
Mycophenolate Mofetil
500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
Radiation Therapy
40.5 Gy in 15 fractions
Re-resection (as part of standard of care)
Re-resection or biopsy of tumor as part of standard of care
Temozolomide
Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT.
Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
Radiation Therapy
60 Gy in 30 fractions
University of Michigan Rogel Cancer Center, Ann Arbor
National Cancer Institute (NCI)
NIH
University of Michigan Rogel Cancer Center
OTHER